Bayfield Drills 35.93 g/t Au over 10.0m within 13.28 g/t Au over 28.0m in Rainy River, NW Ontario

Bayfield Ventures Corp. (TSX-V: BYV) (FWB: B4N) (the "Company") is pleased to announce an additional high grade gold discovery on its 100% owned Burns Block property in the Rainy River District of north-western Ontario. The Burns Block is situated immediately to the east and on strike to Rainy River Resources' (TSX-V: RR) gold project.

Rainy River gold properties claims map: http://www.bayfieldventures.com/i/pdf/BYVRRArea.pdf

Kodiak Exploration Limited (TSX VENTURE: KXL)(FRANKFURT: KX3) is pleased to announce that exploration drilling on the GK target area at the West Geraldton project has intercepted 24.9 metres grading 9.31 gpt gold (78.3 to 103.2 metres) including 8.1 metres grading 27.75 gpt gold (85.1 to 93.2 metres) in drill hole GK10-40. Reinterpretation of past drilling combined with new surface exploration led to the current drilling program in an area that is only two kilometres north of Premier Gold's Hardrock project (GK-Geraldton Kenogamisis; please see map below). This drill hole was part of a four hole program designed to follow up on previously released drill hole GK08-09 which intercepted 1.2 metres grading 5.93 gpt gold from a polymetallic vein hosted by Archean volcanic rocks. This zone is open to the west and down dip, highlighting the exploration potential of the GK target area.

Red Back Mining Inc. (the "Company" or "Red Back") (TSX: RBI) is pleased to report continued Resource growth at its 100% owned Tasiast Gold Mine ("Tasiast") in Mauritania.

Since the previous December 2009 Mineral Resource estimation (February 1, 2010 release) the Measured and Indicated Resource at Tasiast has increased by 2.74Moz to 9.25Moz (a 42% increase) and the Inferred Resource has increased by 0.63Moz to 1.93Moz (a 48% increase) (at cut off grades of 0.2g/t for oxide and 0.5g/t for fresh material).

Golden Predator Corp. (TSX: GPD) (the "Company") is pleased to announce initial results from its diamond and reverse circulation drilling programs on its Clear Creek Project.

Clear Creek To date the Company has drilled 4 HQ oriented core diamond drill holes totaling 1,054 m and 38 RC drill holes totaling 2,589 m on four separate target areas at its Clear Creek Property. Results for 1 diamond drill hole and 7 of the RC drill holes on the Bear Paw Breccia zone have now been received and analyzed. A detailed plan map and drill hole results table is available for viewing at the Company's website http://www.goldenpredator.com/i/pdf/GP-NR10-28-ClearCreekResults-Sept7-2010-LONG.pdf

Stillwater to Acquire Marathon PGM's Platinum Group Assets; Marathon PGM to Spin Out Gold Assets Acquisition of Complementary Assets Solidifies Stillwater's Position as Leading North American PGM Mining Company; Anticipated to Increase Stillwater's Platinum and Palladium Production by Approximately 40% Within Three Years Transaction Expected to Be Immediately Accretive to Stillwater on a Net Asset Value per Share and Reserve per Share Basis; Expected to Be Highly Accretive to Stillwater Cash Flow Within Three Years

Stillwater Mining Company (NYSE: SWC) ("Stillwater") and Marathon PGM Corporation (TSX: MAR) ("Marathon PGM") today announced that they have entered into a definitive agreement (the "Agreement") pursuant to which Stillwater, by way of a plan of arrangement, will acquire all of the outstanding shares of Marathon PGM.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

The Phase IIb study will assess Serdaxin’s efficacy as a treatment for major depressive disorder in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will be conducted at multiple sites in the U.S. and will measure the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary efficacy endpoint.

Casey’s Receives Preliminary Proposal from Strategic Third Party for Consensual Transaction at $40 Per Share In Cash; While the Board Firmly Believes $40 Per Share Substantially Undervalues Casey’s, It Has Authorized Discussions With the Third Party To Explore Whether a Transaction Can Be Reached That Reflects Casey’s True Value and Is In the Best Interests of Casey’s, Its Shareholders and Other Constituencies

Casey’s Reports Majority of Post-Recapitalization Shareholders Did Not Tender into Casey’s Self-Tender Even at $40 Per Share

Casey’s Reports Solid First Quarter Fiscal 2011 Results and Signs Commitments to Acquire 52 Stores By End of Calendar Year

Eldorado Gold Corporation (TSX: ELD)(NYSE: EGO)(ASX: EAU) ("Eldorado" the "Company" or "we") today confirmed it has approached the Board of Directors of Andean Resources Limited ("Andean") with a proposal to combine the two companies, thus creating the world's fastest growing and lowest cost gold producer.

Andean is a dual listed company (TSX: AND)(ASX: AND) whose main asset is the Cerro Negro Gold Project ("Cerro Negro") in the southern province of Santa Cruz in Argentina. Cerro Negro is an epithermal gold deposit at feasibility study stage that currently contains 2.1 million oz of gold and 20.6 million oz of silver in Probable Reserves.

Q3 Non-GAAP EPS of $0.28 Exceeds Guidance Guidance Raised for Fiscal 2010; Company Expects to Report Non-GAAP EPS of $0.60 to $0.70 per Diluted Share for this Fiscal Year

Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today announced financial results for its third quarter ended July 31, 201Net revenue for the third fiscal quarter was $354.1 million, a sharp increase compared to $94.9 million reported for the same quarter of fiscal 2009.

Take-Two attributed its significantly better-than-expected results for the fiscal 2010 third quarter primarily to the strong performance of Red Dead Redemption, which has sold in more than 6.9 million units worldwide since its launch in May 2010.

Fifth Consecutive Quarter of Double-Digit Growth Drives Record Revenues of $207.9 Million

Revenues Up 10.3% From Prior Quarter and 61.5% From Prior Year Net Income From Continuing Operations Sets a New Record

COMMENTARY "In our just completed first quarter, we reached our previous target financial model earlier than we had predicted," said Jerry Rawls, Finisar's executive Chairman of the Board.

Richfield Ventures Corp. (TSX.V:RVC) ("Richfield" or the "Company") is pleased to report drill results for six more diamond drill holes on the 100% owned portion of its Blackwater Gold Project located approximately 100 km south of Vanderhoof, BC.

The drilling targeted projected extensions west of the known mineralization in previously released drill hole BW 68 (227 metres of 1.51 g/t Au including 66 metres of 3.65 g/t -see NR July 26, 2010). It also tested extensions to the east and south of previously reported drill hole BW 64 (267 metres of 1.57 g/t Au, including 32 metres of 5.46 g/t Au -see NR July 26, 2010). Four holes are reported west of BW 68 and two east and south of BW 64 as follows.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, under its Clinical Trials Agreement with Oncolytics. Oncolytics will provide clinical supplies of REOLYSIN for this study. The Study Chair will be Dr. David E. Cohn of The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Tethys Petroleum Limited ("Tethys" or the "Company") (TSX: TPL) today gave a brief update on its operations in Kazakhstan focused on its oil exploration and appraisal program.

The AKD03 (Dione) exploration well is currently at a depth of 2,823 metres (in what is interpreted to be the middle Jurassic sequence) and casing has been run. Hydrocarbons have been indicated from drilling and log data in three zones and a testing programme is planned for the near future. Once this testing programme has been carried out the well will be drilled deeper into the Triassic sequence.

The G6RE (Dodone) well has now been drilled to a depth of 2,835 metres in order to test a deeper potential oil bearing zone identified from the wireline logs in the original G6 hole. The hole is currently being prepared to run casing but differential sticking in the bottom section probably caused by higher formation pressures and permeable zones has slowed down the process. Once casing has been run, preparations for testing can commence.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

The article offers data demonstrating that RX-8243, an isoquinolineamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®) resistant HCT-15 human colorectal cancer cells and the growth of tumor in in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.

Sycamore Networks, Inc. (NASDAQ: SCMR), today reported its results for the fourth quarter and fiscal year ended July 31, 2010. Revenue for the fourth quarter of fiscal 2010 was $22.2 million, compared with $17.2 million for the fourth quarter of fiscal 2009. Revenue for fiscal 2010 was $68.6 million compared to $67.4 million in fiscal 2009.

Net income for the fourth quarter of fiscal 2010, on a generally accepted accounting principles (“GAAP”) basis, was $0.5 million, or $0.02 per diluted share, compared with a GAAP net loss of $34.9 million, or $1.23 per share for the fourth quarter of fiscal 2009. Net loss for fiscal 2010, on a GAAP basis, was $14.8 million, or $0.52 per share, compared with a GAAP net loss of $53.6 million, or $1.89 per share for fiscal 2009.

Orexigen® Therapeutics, Inc. (Nasdaq:OREX ) and Takeda Pharmaceutical Company Limited , today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

Contrave is a combination therapy believed to address both biological and behavioral drivers of obesity. The central pathways targeted by this treatment are involved in controlling the balance of food intake and metabolism, and regulating reward-based eating behavior.  Orexigen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave on March 31, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011.

Prospero Silver Corp (TSX VENTURE:PSL) (the "Company") is pleased to report the results of Phase 1 drilling at its Baborigame project in southwestern Chihuahua state, Mexico. The project area has a total of 9 vein systems some of which had historic mining. In this first drilling program, 4 of the veins were drilled. Highlights include diamond drill hole PBAB-10-11 with 13 g/t Au and 24.5 g/t Ag over a core length of 3.12 meters; diamond drill hole PBAB-10-09 with 6.1 g/t Au and 75.2 g/t Ag over a core length of 1.4 meters, and diamond drill hole PBAB-10-08 with 2.3 g/t Au and 11 g/t Ag over a core length of 1.58 mts. All three intersections were under the historic Los Angeles mine (see figure at bottom of this News Release). Three other vein systems were drilled in the district including the Diente de Oso vein; the Encerredora North vein and the Cebollas vein (one drill hole). The following table exhibits the results of all the drill holes:

ProAssurance Corporation (NYSE: PRA) and American Physicians Service Group, Inc. (Nasdaq: AMPH) today announced they have entered into an agreement which calls for ProAssurance to acquire all the outstanding shares of American Physicians Service Group, Inc. (APS) in an all-cash transaction for $32.50 per share. The transaction is expected to close by year-end.

"This is an attractive strategic and financial acquisition for ProAssurance," said ProAssurance's Chairman and Chief Executive Officer, W. Stancil Starnes. "APS is the second largest writer of medical professional liability (MPL) insurance in Texas, so we expect this transaction to give ProAssurance a strong market presence in a state that has one of the most stable medical/legal environments in the country. In addition, APS' growth in Oklahoma and Arkansas complements our long-term commitment to those two markets. Financially, we anticipate this transaction will be accretive to our 2011 earnings, before one-time transaction and any restructuring costs."

Kenexa Corporation (Nasdaq: KNXA) and Salary.com, Inc. (Nasdaq: SLRY) today announced that they have entered into an agreement for Kenexa’s acquisition of Salary.com in an all cash tender offer and merger for $4.07 per share, or approximately $80 million. Kenexa, a global provider of business solutions for human resources, expects to complete the cash tender offer and close the transaction during the fourth quarter of 2010. The completion of the transaction is subject to a majority of the outstanding Salary.com shares being tendered, as well as satisfactory completion of other customary closing conditions, including certain regulatory approvals.

Kenexa expects to finance the deal through a combination of its cash balances and borrowings against its credit facility, which was recently put in place. The agreement has been unanimously approved by the board of directors of both companies, and Salary.com’s board intends to recommend that the Salary.com stockholders tender their shares in the offer.

Rainy River Resources Ltd. ("Rainy River" or the "Company") (TSX VENTURE: RR) is pleased to announce drill results from the Rainy River Gold Project in Northwestern Ontario.

Highlights

-- Early results from infill drilling in ODM and 433 Zones are exceptional -- ODM zone infill drilling yields 407.9 g/t gold over 4.5 metres -- 433 zone highlights open pit and underground potential with 1.68 g/t gold over 48.0 metres and 8.27 g/t gold over 4.5 metres -- New HS zone intercept demonstrates potential at depth